Palacka, Patrik http://orcid.org/0000-0003-4505-0952
Janega, Pavol
Polakova, Hana
Slopovsky, Jan
De Angelis, Valentina
Mego, Michal
Article History
Received: 10 January 2022
Accepted: 13 July 2022
First Online: 18 July 2022
Declarations
:
: The patient was treated with atezolizumab within the SAUL study (clinicaltrials.gov: NCT02928406). Informed consent was signed before enrollment.
: Written informed consent for publication of clinical details and clinical images were obtained from the patient prior to his death.
: The authors declare that they have no competing interests.